SAN DIEGO, CA / ACCESSWIRE / March 8, 2022 / Sharp HealthCare, in collaboration with Nascent Biotech, Inc, announced today, its participation in a clinical trial for a novel investigational immunotherapy treatment for patients with glioblastoma GBM, the deadliest form of brain cancer.Pritumumab PTB is a unique monoclonal antibody that attacks cancers originating in the cells lining an organ ... Lire le communiqué |
|
|
|
|
Milestone Payment is the Second of Four in $5M Pritumumab Licensing DealVERO BEACH, FL / ACCESSWIRE / February 23, 2022 / Nascent Biotech, Inc. OTCQB:NBIO "Nascent Biotech", "Nascent", or the "Company", a clinicalstage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to... Lire le communiqué |
|
|
|
|
VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. OTCQB:NBIO "Nascent Biotech", "Nascent", or the "Company", a clinicalstage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of dosing of the second cohort of patients... Lire le communiqué |
|
|
|
|